ARS Pharmaceuticals (SPRY) Assets Average (2021 - 2026)

ARS Pharmaceuticals (SPRY) has 6 years of Assets Average data on file, last reported at $307.6 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 9.32% year-over-year to $307.6 million; the trailing twelve-month figure through Mar 2026 stood at $307.6 million (down 9.32% YoY), and the FY2025 full-year result was $339.4 million, up 16.17% from the prior year.
• Assets Average slipped to $307.6 million in Q1 2026, from $350.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $350.2 million in Q4 2025 to a low of $187.0 million in Q1 2022.
• A 5-year average of $276.7 million and a median of $276.3 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average sank 51.88% in 2022 and jumped 56.13% in 2025, its largest moves.
• Tracing SPRY's Assets Average over 5 years: stood at $276.2 million in 2022, then slipped by 12.81% to $240.9 million in 2023, then grew by 18.06% to $284.4 million in 2024, then advanced by 23.16% to $350.2 million in 2025, then retreated by 12.17% to $307.6 million in 2026.
• Business Quant data shows SPRY's Assets Average at $307.6 million in Q1 2026, $350.2 million in Q4 2025, and $343.1 million in Q3 2025.